Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123–7. https://doi.org/10.1002/cncr.26679.

Article  PubMed  Google Scholar 

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–7. https://doi.org/10.1056/NEJM200104053441401.

Article  CAS  PubMed  Google Scholar 

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40. https://doi.org/10.1200/jco.2015.64.8899.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–53. https://doi.org/10.1038/s41375-020-01111-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, Le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825–33. https://doi.org/10.1038/s41375-022-01589-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138(21):2042–50. https://doi.org/10.1182/blood.2021012082.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031–41. https://doi.org/10.1182/blood.2020009984.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes J, Hughes T, Mauro M, Hochhaus A, Rea D, Goh YT, et al. Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: primary efficacy and safety results from a phase 1 trial. Blood. 2020;136:47–50. https://doi.org/10.1182/blood-2020-139677.

Article  Google Scholar 

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen J, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv41–51. https://doi.org/10.1093/annonc/mdx219.

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network. Chronic myeloid leukemia (version 1.2023). https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf

Atallah E, Sweet K. Treatment-free remission: the new goal in CML therapy. Curr Hematol Malignancy Rep. 2021;16(5):433–9. https://doi.org/10.1007/s11899-021-00653-1.

Article  Google Scholar 

Ortman J VV, Hogan H. An aging nation: the older population in the United States. https://www.census.gov/prod/2014pubs/p25-1140.pdf.

Latagliata R, Carmosino I, Vozella F, Volpicelli P, De Angelis F, Loglisci MG, et al. Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a ‘real-life’ patient population with chronic myeloid leukaemia. Hematol Oncol. 2017;35(2):232–6. https://doi.org/10.1002/hon.2274.

Article  CAS  PubMed  Google Scholar 

Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace. 2014;16(1):101–8. https://doi.org/10.1093/europace/eut214.

Article  PubMed  Google Scholar 

Halfdanarson OO, Pottegard A, Bjornsson ES, Lund SH, Ogmundsdottir MH, Steingrimsson E, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol. 2018;11:1756284818777943. https://doi.org/10.1177/1756284818777943.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life Expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–7. https://doi.org/10.1200/JCO.2015.66.2866.

Article  CAS  PubMed  Google Scholar 

Jamy O, Godby R, Sarmad R, Costa LJ. Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: a US population-based study. Am J Hematol. 2021;96(7):E265–E8. https://doi.org/10.1002/ajh.26195.

Article  CAS  PubMed  Google Scholar 

Radivoyevitch T, Weaver D, Hobbs B, Maciejewski JP, Hehlmann R, Jiang Q, et al. Do persons with chronic myeloid leukaemia have normal or near normal survival? Leukemia. 2020;34(2):333–5. https://doi.org/10.1038/s41375-019-0699-y.

Article  PubMed  Google Scholar 

USA facts. https://usafacts.org/data/topics/people-society/population-and-demographics/population-data/population/.

Cancer Stat Facts: Leukemia - chronic myeloid leukemia (CML) 2018. https://seer.cancer.gov/statfacts/html/cmyl.html.

Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics—2021 Update. Circulation. 2021;143(8):e254–743. https://doi.org/10.1161/CIR.0000000000000950.

Article  PubMed  Google Scholar 

Ford ES, Giles WH, Mokdad AH. The distribution of 10-Year risk for coronary heart disease among U.S. adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol. 2004;43(10):1791–6. https://doi.org/10.1016/j.jacc.2003.11.061.

Article  PubMed  Google Scholar 

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84. https://doi.org/10.1038/s41375-020-0776-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banegas MP, Rivera DR, O'Keeffe-Rosetti MC, Carroll NM, Pawloski PA, Tabano DC, et al. Long-term patterns of oral anticancer agent adoption, duration, and switching in patients with CML. J Natl Compr Canc Netw. 2019;17(10):1166–72. https://doi.org/10.6004/jnccn.2019.7303. Large retrospective review of real-world treatment patterns of oral and non-oral therapies for CML dating back to the 2000s including lines of therapy and trends in the use of TKIs

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turkina A, Wang J, Mathews V, Saydam G, Jung CW, Al Hashmi HH, et al. TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. Br J Haematol. 2020;190(6):869–76. https://doi.org/10.1111/bjh.16599.

Article  PubMed  Google Scholar 

Shallis RM, Wang R, Bewersdorf JP, Zeidan AM, Davidoff AJ, Huntington SF, et al. Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Ther Adv Hematol. 2021;12:20406207211043404. https://doi.org/10.1177/20406207211043404.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henk HJ, Woloj M, Shapiro M, Whiteley J. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clin Ther. 2015;37(1):124–33. https://doi.org/10.1016/j.clinthera.2014.10.019.

Article  PubMed  Google Scholar 

Seo HY, Ko TH, Hyun SY, Song H, Lim ST, Shim KY, et al. Tyrosine kinase inhibitor dosing patterns in elderly patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2019;19(11):735–43.e2. https://doi.org/10.1016/j.clml.2019.08.009.

Article  PubMed  Google Scholar 

Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, et al. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017;92(11):1214–23. https://doi.org/10.1002/ajh.24887. A large prospective observational study which evaluated TKI use and management patterns in the first-line setting for patients with CML. Highlighted gaps in adherence to monitoring recommendations when initiating patients on TKI therapy

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019;94(1):46–54. https://doi.org/10.1002/ajh.25306. Provides prospective observational data on treatment interruptions and switching TKI therapy in routine clinical practice

Article  CAS  PubMed  Google Scholar 

Latagliata R, Capodanno I, Miggiano MC, Iurlo A, Cavazzini F, Crescenzi SL, et al. Permanent discontinuation of tyrosine kinase inhibitor frontline therapy in patients with chronic phase chronic myeloid leukemia patients during the first 36 months of treatment: a “Campus CML” study. Blood. 2022;140(Supplement 1):3906–7. https://doi.org/10.1182/blood-2022-170415. A large retrospective review of ~1000 CML patients showing that nearly one-third of patients permanently discontinue frontline TKI therapy in the first 3 years of treatment due to resistance or toxicity

Article  Google Scholar 

Ota S, Matsukawa T, Yamamoto S, Ito S, Shindo M, Sato K, et al. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Eur J Haematol. 2018;101(1):95–105. https://doi.org/10.1111/ejh.13081.

Article  CAS  PubMed  Google Scholar 

Vener C, Banzi R, Ambrogi F, Ferrero A, Saglio G, Pravettoni G, et al. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv. 2020;4(12):2723–35. https://doi.org/10.1182/bloodadvances.2019001329. A recent systemic review and meta-analysis comparing first-line imatinib to second- and third-generation TKIs, including several major clinical trials (ENEST, DASISION, BFORE, NordCML006)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gurion R, Raanani P, Vidal L, Leader A, Gafter-Gvili A. First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response – systematic review and meta-analysis. Acta Oncol. 2016;55(9-10):1077–83. https://doi.org/10.1080/0284186x.2016.1201214.

Article  CAS  PubMed  Google Scholar 

Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, et al. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol Assess. 2012;16(42):iii–v. https://doi.org/10.3310/hta16420.

Article  CAS  PubMed  Google Scholar 

Tang L, Zhang H, Peng YZ, Li CG, Jiang HW, Xu M, et al. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis. BMC Cancer. 2019;19(1):849.